We analyzed, whether the therapy of ERα-positive human breast cancer cell lines MCF7 and T47D with 4-OHT can be optimized by an anti-metabolism therapy using 2-DG and/or CB-839 and whether differences to the corresponding tamoxifen-resistant sublines MCF7-TR and T47D-TR could be observed. This evidence concerns the gene ESR1 and breast carcinoma.